Caris Life Sciences Expands PTEN Testing for Prostate Cancer
IRVING, Texas — July 14, 2026 Caris Life Sciences has expanded its precision oncology portfolio with the launch of...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
IRVING, Texas — July 14, 2026 Caris Life Sciences has expanded its precision oncology portfolio with the launch of...
WASHINGTON, D.C., April 30, 2026 AstraZeneca announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC)...
